Gland Pharma gets USFDA EIR for Pashamylaram facility

Published On 2023-11-25 06:18 GMT   |   Update On 2023-11-28 12:00 GMT

Hyderabad: Gland Pharma has recently announced that the Company has received an Establishment Inspection Report (EIR) from the US FDA indicating the closure of the inspection at the Company’s Pashamylaram Facility in Hyderabad.The USFDA inspected the facility between 23rd August, 2023 and 26th August, 2023."Further to our intimation dated August 26, 2023; this is to inform you that...

Login or Register to read the full article

Hyderabad: Gland Pharma has recently announced that the Company has received an Establishment Inspection Report (EIR) from the US FDA indicating the closure of the inspection at the Company’s Pashamylaram Facility in Hyderabad.

The USFDA inspected the facility between 23rd August, 2023 and 26th August, 2023.

"Further to our intimation dated August 26, 2023; this is to inform you that following the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) by US FDA at the Company’s Pashamylaram Facility at Hyderabad between 23rd August, 2023 and 26th August, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection," Gland Pharma stated in a BSE filing.

Gland Pharma, a generic injectable-focused pharmaceutical company, was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News